Martin Samuel Bates 4
4 · Celldex Therapeutics, Inc. · Filed Aug 15, 2022
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2022-08-11$9.02/sh+2,453$22,117→ 26,831 total - Sale
Common Stock
2022-08-11$37.04/sh−2,453$90,856→ 24,378 total - Exercise/Conversion
Common Stock
2022-08-12$9.02/sh+3,876$34,948→ 28,254 total - Exercise/Conversion
Common Stock
2022-08-12$2.78/sh+13,671$38,005→ 41,925 total - Sale
Common Stock
2022-08-12$36.76/sh−14,261$524,304→ 27,664 total - Sale
Common Stock
2022-08-12$35.38/sh−2,065$73,053→ 25,599 total - Sale
Common Stock
2022-08-12$34.62/sh−1,221$42,272→ 24,378 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-11−2,453→ 7,077 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (2,453 underlying) - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-12−3,876→ 3,201 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (3,876 underlying) - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-12−13,671→ 10,750 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (13,671 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]As of June 13, 2022, the option is fully vested.
- [F6]25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.